Table 5.
Covariate analysis
| Covariate | Level | Events (%) | HR estimatea | 95% CI | p valueb |
|---|---|---|---|---|---|
| ECOG | 0-Fully active | 58.7% (352/600) | 1.000 | ||
| 1-Restricted | 73.2% (246/336) | 1.513 | [1.280, 1.789] | < 0.0001 | |
| 2 or higher | 70.0% (56/80) | 1.624 | [1.217, 2.168] | ||
| Extra-hepatic disease prior to treatment | No | 59.0% (426/722) | 1.000 | ||
| Yes | 76.7% (234/305) | 1.372 | [1.149, 1.638] | < 0.0001 | |
| Cirrhosis | No | 65.6% (463/706) | 1.000 | ||
| Yes | 61.4% (197/321) | 1.304 | [1.063, 1.599] | 0.0128 | |
| Ascites | No | 63.6% (588/925) | 1.000 | ||
| Yes | 70.6% (72/102) | 1.344 | [1.035, 1.746] | 0.0039 | |
| Tumour to liver percentage | Less than 10% | 59.0% (242/410) | 1.000 | ||
| 10%–20% | 62.0% (127/205) | 1.137 | [0.914, 1.413] | 0.0195 | |
| Greater than 20% | 66.8% (147/220) | 1.414 | [1.143, 1.750] | ||
| Unknown | 75.0% (144/192) | 1.098 | [0.879, 1.373] | ||
| Location of liver tumours | Bilobar | 71.4% (419/587) | 1.000 | ||
| Left only | 57.0% (57/100) | 0.790 | [0.589, 1.059] | 0.0024 | |
| Right only | 54.3% (184/339) | 0.694 | [0.572, 0.843] | ||
| Prior chemotherapy: number of lines | 0 | 57.4% (296/516) | 1.000 | ||
| 1 | 64.4% (123/191) | 1.176 | [0.931, 1.485] | < 0.0001 | |
| 2–5 | 76.8% (172/224) | 1.855 | [1.493, 2.303] | ||
| 6 or more | 72.5% (66/91) | 1.355 | [1.010, 1.818] |
aA hazard ratio above 1 implies a higher rate of non-survival for that category compared to the reference category (for which the hazard ratio is 1.000). Selection of covariates based on a stepwise procedure. Variables that did not qualify (p > 0.05) were: sex (p = 0.2800), prior systemic therapy (p = 0.2664), prior hepatic procedures (p = 0.0895) and number of liver tumours (p = 0.0964)
bP values are from global Wald test